JP2025511399A5 - - Google Patents

Info

Publication number
JP2025511399A5
JP2025511399A5 JP2024559031A JP2024559031A JP2025511399A5 JP 2025511399 A5 JP2025511399 A5 JP 2025511399A5 JP 2024559031 A JP2024559031 A JP 2024559031A JP 2024559031 A JP2024559031 A JP 2024559031A JP 2025511399 A5 JP2025511399 A5 JP 2025511399A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
administration
standard therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/017805 external-priority patent/WO2023196545A1/en
Publication of JP2025511399A publication Critical patent/JP2025511399A/ja
Publication of JP2025511399A5 publication Critical patent/JP2025511399A5/ja
Pending legal-status Critical Current

Links

JP2024559031A 2022-04-08 2023-04-07 Ｍｔａ協同的ｐｒｍｔ５阻害剤を使用する癌の処置 Pending JP2025511399A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263329010P 2022-04-08 2022-04-08
US63/329,010 2022-04-08
US202263345736P 2022-05-25 2022-05-25
US63/345,736 2022-05-25
PCT/US2023/017805 WO2023196545A1 (en) 2022-04-08 2023-04-07 Cancer treatments using mta-cooperative prmt5 inhibitors

Publications (2)

Publication Number Publication Date
JP2025511399A JP2025511399A (ja) 2025-04-15
JP2025511399A5 true JP2025511399A5 (enExample) 2025-07-28

Family

ID=86328467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559031A Pending JP2025511399A (ja) 2022-04-08 2023-04-07 Ｍｔａ協同的ｐｒｍｔ５阻害剤を使用する癌の処置

Country Status (14)

Country Link
US (1) US20250228861A1 (enExample)
EP (1) EP4504199A1 (enExample)
JP (1) JP2025511399A (enExample)
KR (1) KR20240169712A (enExample)
CN (1) CN119317435A (enExample)
AU (1) AU2023249277A1 (enExample)
CA (1) CA3255376A1 (enExample)
CL (1) CL2024003040A1 (enExample)
IL (1) IL315996A (enExample)
JO (1) JOP20240223A1 (enExample)
MX (1) MX2024012431A (enExample)
TW (1) TW202345844A (enExample)
WO (1) WO2023196545A1 (enExample)
ZA (1) ZA202407596B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202440126A (zh) * 2022-11-30 2024-10-16 美商安進公司 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療
WO2024137778A1 (en) * 2022-12-21 2024-06-27 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
TW202527950A (zh) * 2023-10-06 2025-07-16 美商安進公司 使用ｍｔａ協作的ｐｒｍｔ５抑制劑的癌症治療
WO2025092818A1 (zh) * 2023-10-31 2025-05-08 康百达（四川）生物医药科技有限公司 一种吡啶衍生物及其在医药上的应用
CN121889382A (zh) * 2023-11-08 2026-04-17 北京泰德制药股份有限公司 Prmt5抑制剂及其制备方法
TW202532070A (zh) * 2023-12-01 2025-08-16 大陸商上海翰森生物醫藥科技有限公司 四並環類衍生物抑制劑、其製備方法和應用
WO2025157284A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和化疗剂的药物组合物
CN121398850A (zh) * 2024-01-26 2026-01-23 上海湃隆生物科技有限公司 包含prmt5抑制剂和egfr抑制剂的药物组合物
WO2025176054A1 (zh) * 2024-02-20 2025-08-28 华润医药研究院（深圳）有限公司 三环杂环类化合物及其制备方法和医药用途
WO2025194059A1 (en) * 2024-03-15 2025-09-18 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with taxane anticancer agent
TW202602455A (zh) * 2024-03-26 2026-01-16 美商安進公司 使用ｍｔａ協作的ｐｒｍｔ５抑制劑的癌症治療
TW202606706A (zh) * 2024-04-05 2026-02-16 美商安進公司 使用ｍｔａ協作的ｐｒｍｔ５抑制劑的胃腸癌治療
WO2025250569A1 (en) * 2024-05-29 2025-12-04 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors
WO2025265110A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Oral pharmaceutical compositions comprising a naphthyridine compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021551951A1 (en) * 2019-02-13 2022-07-18 Les Laboratoires Servier Sas Combination therapies for use in treating cancer
CA3170321A1 (en) * 2020-02-12 2021-08-19 Amgen Inc. Novel prmt5 inhibitors
US11845760B2 (en) * 2020-12-16 2023-12-19 Amgen Inc. PRMT5 inhibitors

Similar Documents

Publication Publication Date Title
JP5416328B2 (ja) 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用
Higuchi et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2)
Bunn Jr et al. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
CN102105152B (zh) 包含cdks抑制剂和抗肿瘤剂的治疗组合
JP2012515184A (ja) 大腸がんの治療方法
JP2017505321A5 (enExample)
JP2003533485A5 (enExample)
JP2020523356A5 (enExample)
JP2024524461A5 (enExample)
JP2022526159A5 (enExample)
JP2024513575A5 (enExample)
JP2009536956A (ja) 抗癌治療法
Tewes et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study
CN1424912A (zh) 用于治疗癌症的含有喜树碱和嘧啶衍生物的组合物
Takahashi et al. Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration
US10080807B2 (en) Combination chemotherapy comprising a liposomal prodrug of mitomycin C
RU2005126819A (ru) Усовершенствованное лечение опухолей
JP2024538719A5 (enExample)
WO2017135412A1 (ja) 重度腎機能障害を有する癌患者に対する治療方法
Hahn et al. Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer
JP2024515215A5 (enExample)
Vokes et al. Adjuvant and neoadjuvant treatments for NSCLC
Smith The impact of doxorubicin dose intensity on survival of patients with Ewing's sarcoma.
JPWO2022260132A5 (enExample)
JP2023514426A5 (enExample)